Yasuyuki Mizutani

Yasuyuki Mizutani

Auto-generated profile, based on publicly available information

Yasuyuki Mizutani

Department of Gastroenterology and Hepatology Nagoya University Graduate School of Medicine Nagoya Aichi Japan

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 February 2022 in Diagnostics
Verified
Journal Article
Open access
PDF file
Takuya IshikawaTakuya Ishikawa
Takuya Ishikawa
MHMasato Hayakawa
Masato Hayakawa
HSHirotaka Suzuki
Hirotaka Suzuki
EOEizaburo Ohno
Eizaburo Ohno
YMYasuyuki Mizutani
Yasuyuki Mizutani
KHKazuhiro Hotta
Kazuhiro Hotta
We aimed to develop a new artificial intelligence (AI)-based method for evaluating endoscopic ultrasound-guided fine-needle biopsy (EUS-FNB) specimens in pancreatic diseases using deep learning and contrastive learning. We analysed a total of 173 specimens from 96 patients who underwent EUS-FNB with a 22 G Franseen needle for pancreatic diseases. In the initial study, the deep learning method based on stereomicroscopic images of 98 EUS-FNB specimens from 63 patients showed an accuracy of 71.8% for predicting the histological diagnosis, which was lower than that of macroscopic on-site evaluation (MOSE) performed by EUS experts (81.6%). Then, we used image analysis software to mark the core tissues in the photomicrographs of EUS-FNB specimens after haematoxylin and eosin staining and verified whether the diagnostic performance could be improved by applying contrastive learning for the features of the stereomicroscopic images and stained images. The sensitivity, specificity, and accuracy of MOSE were 88.97%, 53.5%, and 83.24%, respectively, while those of the AI-based diagnostic method using contrastive learning were 90.34%, 53.5%, and 84.39%, respectively. The AI-based evaluation method using contrastive learning was comparable to MOSE performed by EUS experts and can be a novel objective evaluation method for EUS-FNB.

7 July 2022 in Cancers
Verified
Journal Article
Open access
PDF file
RARyota Ando
Ryota Ando
ASAkihiro Sakai
Akihiro Sakai
TITadashi IIDA
Tadashi IIDA
KKKunio Kataoka
Kunio Kataoka
YMYasuyuki Mizutani
Yasuyuki Mizutani
Atsushi EnomotoAtsushi Enomoto
Atsushi Enomoto
A well-known feature of human pancreatic ductal adenocarcinoma (PDAC) is the extensive proliferation of cancer-associated fibroblasts (CAFs) and highly fibrotic stroma. Recent evidence, based mainly on single-cell analyses, has identified various subsets of CAFs in PDAC mouse models. However, we do not know how these CAF subsets are involved in the progression and drug resistance of human PDAC. Additionally, it remains unclear whether these diverse CAFs have distinct origins and are indicators of genuinely distinct CAF lineages or reflect different states of the same CAFs depending on the tumor microenvironment. Interestingly, recent preclinical studies have started to characterize the nature of cancer-restraining CAFs and have identified their markers Meflin and collagen type I alpha 1. These studies have led to the development of strategies to induce changes in CAF phenotypes using chemical reagents or recombinant viruses, and some of them have been tested in clinical studies. These strategies have the unique potential to convert the so-called bad stroma to good stroma and may also have therapeutic implications for non-cancer diseases such as fibrotic diseases. Together with recently developed sophisticated strategies that specifically target distinct CAF subsets via adoptive cell transfer therapy, vaccination, and antibody–drug conjugates, any future findings arising from these clinical efforts may expand our understanding of the significance of CAF diversity in human PDAC.

1 June 2020 in Digestive Diseases and Sciences
Verified
Journal Article
Closed access
PDF file
TNTakahiro Nishikawa
Takahiro Nishikawa
KMKeiko Maeda
Keiko Maeda
MNMasanao Nakamura
Masanao Nakamura
TYTakeshi Yamamura
Takeshi Yamamura
TSTsunaki Sawada
Tsunaki Sawada
MFMitsuhiro Fujishiro
Mitsuhiro Fujishiro

18 January 2022 in Canadian Journal of Gastroenterology and Hepatology
Verified
Journal Article
Open access
PDF file
Takuya IshikawaTakuya Ishikawa
Takuya Ishikawa
EOEizaburo Ohno
Eizaburo Ohno
YMYasuyuki Mizutani
Yasuyuki Mizutani
TITadashi IIDA
Tadashi IIDA
KUKota Uetsuki
Kota Uetsuki
HKHiroki Kawashima
Hiroki Kawashima
Background/Aims. The usefulness of macroscopic on-site evaluation (MOSE) during endoscopic ultrasound-guided fine-needle biopsy (EUS-FNB) has been reported, but a specific method for MOSE has not been established. We aimed to investigate the usefulness of MOSE using a stereomicroscope (S-MOSE) for the diagnosis of solid pancreatic lesions (SPLs). Methods. We reviewed a total of 60 consecutive patients who underwent both S-MOSE and rapid on-site cytopathological evaluation (ROSE) during EUS-FNB between July 2019 and October 2020, and the usefulness of S-MOSE in comparison with histology was evaluated. A 22-gauge Franseen needle was used to perform EUS-FNB in all patients, and only the specimens obtained by the first pass were evaluated. The final diagnosis was based on the surgical specimen or the clinical course consistent with the EUS-FNB results. Results. The final diagnoses of the 60 patients included 45 patients with pancreatic ductal adenocarcinoma, 6 with autoimmune pancreatitis, 4 with mass-forming pancreatitis, 1 with pancreatic metastasis, 2 with pancreatic neuroendocrine tumor, and 2 with intraductal papillary mucinous carcinoma. The histological diagnostic accuracy of the first pass of EUS-FNB was 83.3 (50/60). The agreement between the S-MOSE and the histological diagnosis was 90 (54/60). The positive predictive value of S-MOSE for histological diagnosis was 90.7, which can be an indicator of when to stop the EUS-FNB procedure. There were no immediate or delayed adverse events reported after the FNB based on the chart and medical visit history review. Conclusion. In the EUS-FNB of SPLs, S-MOSE can be an alternative to ROSE for specimen evaluation and has the potential to shorten the procedure time.

29 September 2018 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
MNMasanao Nakamura
Masanao Nakamura
TYTakeshi Yamamura
Takeshi Yamamura
KMKeiko Maeda
Keiko Maeda
TSTsunaki Sawada
Tsunaki Sawada
YMYasuyuki Mizutani
Yasuyuki Mizutani
TGThe Nagoya University Crohn’s Disease Study Group
The Nagoya University Crohn’s Disease Study Group
Mucosal healing in Crohn’s disease (CD) can be evaluated by capsule endoscopy (CE). However, only a few studies have utilized CE to demonstrate the therapeutic effect of medical treatment. We sought to evaluate the validity of using CE to monitor the effect of medical treatment in patients with CD. One hundred (n = 100) patients with CD were enrolled. All patients had a gastrointestinal (GI) tract patency check prior to CE. Patients with baseline CE Lewis score (LS) ≤ 135 were included in the non-active CD group and ended the study. In those with LS > 135 (active CD group), additional treatment was administered, regardless of symptoms, as per the treating clinician’s advice. Patients of the active CD group underwent follow-up CE assessment 6 months later. Out of 92 patients with confirmed GI patency who underwent CE, 40 (43.4%) had CE findings of active inflammation. Of 29 patients with LS > 135 who received additional medications and underwent follow-up CE, improvement of the LS was noted in 23 (79.3%) patients. Eleven patients were asymptomatic but received additional medications; 8 (72.7%) had improvement of the LS. This study demonstrated that additional treatment even for patients with CD in clinical remission and active small-bowel inflammation on CE can reduce mucosal damage.

1 January 2021 in Canadian Journal of Gastroenterology and Hepatology
Verified
Journal Article
Open access
PDF file
MNMasanao Nakamura
Masanao Nakamura
TYTakeshi Yamamura
Takeshi Yamamura
KMKeiko Maeda
Keiko Maeda
TSTsunaki Sawada
Tsunaki Sawada
YMYasuyuki Mizutani
Yasuyuki Mizutani
MFMitsuhiro Fujishiro
Mitsuhiro Fujishiro
Introduction. Ischemic enteritis (IE) is a relatively rare small bowel disease that is diagnosed via double‐balloon endoscopy (DBE), although the lack of established diagnostic criteria can make it difficult to confirm the diagnosis. This study aimed to describe the clinical characteristics, endoscopic imaging features, and treatments for IE at our center. Patients and Methods. We retrospectively searched the DBE database (1,521 patients) at Nagoya University Hospital for patients with IE and collected data regarding endoscopic findings, clinical background, and histological findings. The cases were categorized according to whether they involved transient or stenotic IE. Results. The DBE database included 24 patients (14 men) with IE. Transient IE was identified in 9 patients, and stenotic IE was identified in 15. Half of the patients had a history of cerebrovascular and cardiovascular disease. A granular structure at the ulcer base was the most frequently observed DBE finding at the stenotic site. Enterography using the contrast medium revealed that transient IE had a similar stenotic lesion length, relative to stenotic IE, although stenotic IE had a significantly higher stenosis ratio (81% vs. 63%, P = 0.033). Small bowel enteroclysis revealed the “lead pipe” sign (11 patients), thumbprinting (3 patients), and the serrated lumen sign (1 patient). Only 1 patient with stenotic IE experienced recurrence after conservative treatment. Conclusion. During DBE, IE was characterized by cannular stenosis with extended and variable ulceration types, which spread over the edge of the stenosis, and a granular appearance at the ulcer base. These findings may help guide the diagnosis of IE.